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Abstract
Background: Ovarian insufficiency is a major concern for long-term cancer survivors. Although semen freezing is
well established to preserve male fertility, the possibilities to secure post-cancer female fertility are mostly limited to
oocyte or embryo freezing. These methods require time-consuming ovarian stimulation with or without in vitro
fertilization (IVF) that evidently delays cancer therapy. Ovarian tissue cryopreservation and subsequent thawed tissue
autotransplantation are considered the most promising alternative strategy for restoring the fertility of oncology
patients, which has not yet received the full clinical acceptance. Therefore, all successful cases are needed to prove
its reliability and safety.
Case presentation: Here we report a single case in Estonia, where a 28-year-old woman with malignant breast
neoplasm had ovarian cortex cryopreserved before commencing gonadotoxic chemo- and radiotherapy. Two years
after cancer therapy, the patient underwent heterotopic ovarian tissue transplantation into the lateral pelvic wall.
The folliculogenesis was stimulated in the transplanted tissue by exogenous follicle-stimulating hormone and
oocytes were collected under ultrasound guidance for IVF and embryo transfer. The healthy boy was born after full-
term gestation in 2014, first in Eastern Europe.
Conclusion: Despite many countries have reported the first implementation of the ovarian tissue freezing and
transplantation protocols, the data is still limited on the effectiveness of heterotopic ovarian transplant techniques.
Thus, all case reports of heterotopic ovarian tissue transplantation and long-term follow-ups to describe the
children’s health are valuable source of clinical experience.
Keywords: Fertility preservation, Ovarian tissue cryopreservation, Heterotopic transplantation, Restoration of
gonadal function, Live birth, Case report
Background
Women are born with roughly one million
follicle-enclosed oocytes, with the vast majority of them
undergoing atresia and only 300–400 fully matured eggs
becoming available for fertilization during the entire
woman’s reproductive life-span. In addition, the ovaries
are very sensitive to different medical treatments,
particularly cytotoxic treatments of oncotherapies, such
as using alkylating agents and ionizing radiation, render-
ing women with cancer prematurely sterile due to the
iatrogenic manipulations [1, 2]. The improvements in
cancer treatments over the last decades have resulted in
vastly increased numbers of long-term survivors, while
the loss of fertility remains as one of the major
life-quality concerns for young women facing potentially
sterilising treatment [1, 3].
Several options are available to preserve fertility in
cancer patients, giving them the opportunity for
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motherhood when they successfully overcome their dis-
ease: immature or mature oocyte cryopreservation; em-
bryo freezing and ovarian tissue cryopreservation [4].
Only the latter is suitable for pre-pubertal girls with im-
mature eggs only and women who cannot delay the start
of chemotherapy and radiation for cancer therapy [4, 5].
Despite the preliminary results are encouraging as
orthotopic reimplantation of cryopreserved ovarian tis-
sue restores ovarian activity in > 95% of women [6], the
location and timing of the transplantation are not fully
studied and unequivocally agreed in clinical guidelines.
Success rate after ovarian tissue reimplantation is stead-
ily increasing and the live birth rate is estimated to be
around 35–40% [6, 7]. The first human live birth as a re-
sult of ovarian cortex reimplantation was reported in 2004
[8], and since then there are > 100 live births reported glo-
bally by multicenter and single case reports [6, 9]. How-
ever, the global access to this procedure remains poor,
which also impedes the evaluation of the overall success
and safety of the method.
Here, we report the first case in Estonia, where a
28-year-old woman with malignant neoplasm of breast
tissue had ovarian cortex cryopreserved for fertility pres-
ervation. The subsequent heterotopic transplantation,
stimulated folliculogenesis, IVF and embryo transfer re-
sulted in a successful pregnancy and a healthy child born
in 2014, being the first live birth after ovarian tissue
transplantation in Eastern Europe. We also report a
spontaneous pregnancy and second live birth in 2017 to
the same patient, demonstrating that the personalised
prediction for fertility restoration is still hard to make.
The health follow-up for both children is also provided,
contributing to the emerging understanding of the over-
all safety of the procedure.
Case presentation
Patient information
We report a case of the patient, a 28-year-old woman with
a regular 28-day menstrual cycle (FSH level 5,1 U/L), who
was diagnosed with carcinoma of the left breast. The over-
all timeline of the medical procedures from cancer diag-
nosis to the birth of a child is shown in Fig. 1.
In cancer diagnosis, the postoperative pathology re-
vealed poorly differentiated invasive ductal high-grade
carcinoma, with negative sentinel node biopsy (pT2 pN0
M0G3 stage IIA by TNM classification) in 2010. The
patient underwent targeted sequencing of cancer tissue
using TruSight Cancer panel (Illumina, Cat No
FC-121-0202) of mutational hotpots in genes predispos-
ing or associated with cancer. Analysis of the targeted
regions did not reveal any cancer-related variants/muta-
tions in BRCA1, BRCA2, PTEN, STK11, CDH1, CHEK2,
BRIP1, ATM, PALB2, NF1 and TP53 genes.
Ovarian tissue cryopreservation
The option of ovarian tissue cryopreservation was of-
fered as fertility preservation because of the time limita-
tion before chemotherapy, as there was not enough time
for hormonal stimulation to produce mature oocytes for
freezing. It was also known that the cancer therapy
planned for the patient (chemotherapy and radiotherapy)
would be highly gonadotoxic and would likely lead to
Fig. 1 Timescale of the patient’s medical history from the diagnosis of the cancer to the successful live birth. A 28-year-old woman with invasive
ductal G3 carcinoma had ovarian cortex cryopreserved before commencing gonadotoxic chemo- and radiotherapy. Two years after cancer
therapy, the patient underwent heterotopic ovarian tissue transplantation into the lateral pelvic wall. The folliculogenesis was stimulated in the
transplanted tissue by exogenous follicle-stimulating hormone and oocytes were collected under ultrasound guidance for IVF and embryo
transfer. The healthy boy was born after full-term gestation, first in Eastern Europe
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premature ovarian insufficiency and a loss of menstrual
cycle activity. The patient granted her written informed
consent for conducting the procedure.
During laparoscopy, two ovarian pieces, sized 1.5 × 1.0
cm, were obtained from both sides, containing ovarian
cortex and medullar part. The ovarian cortex was manu-
ally dissected from medullary tissue in HEPES-buffered
IVF culture media (Origio, Denmark). The cortical part
of the tissue was cut into smaller pieces (1-2 mm × 3-5
mm) with a thickness of 1-2 mm. For cryopreservation,
the cortical slices were incubated with human serum al-
bumin (HSA, 25mg/ml) for 5 min, 1.5M 1,2-propane-
diol (PrOH) for 10 min, and 1.5M PrOH and 0.1M
sucrose for 5 min in PBS (Sigma-Aldrich, Germany) at
room temperature; were transferred to cryovials and
were frozen using slow freezing protocol as described
previously [10].
Adjuvant cancer therapy
After the surgery for breast cancer and laparoscopy to
remove the ovarian tissue, the patient was eligible for
adjuvant chemotherapy and received six cycles of the
FEC regimen containing a sequential combination of
anthracyclines: three cycles of 5-fluorouracil 500 mg/m2
(800mg), epirubicin 80 mg/m2 (130mg) and cyclophos-
phamide 500 mg/m2 (dosage 800 mg intravenous). Since
the patient developed neutropenia during the chemo-
therapy, reduced doses of anthracyclines were adminis-
tered for the last three cycles: 5-fluorouracil (600 mg),
epirubicin (110 mg) and cyclophosphamide (dosage 600
mg). The chemotherapy lasted for 5 months in 2010–
2011, followed by radiotherapy to the breast tissue
(50Gy) and boost to the operation scar (10Gy) for two
months in 2011. The patient developed amenorrhea
shortly after the initiation of chemotherapy. However, no
hormonal tests are available to the authors as they were
made in another hospital.
Ovarian tissue transplantation
After chemo- and radiotherapy-induced amenorrhea, the
patient regained rare spontaneous menstrual cycles at
the beginning of 2012. Her FSH level was 22,1 U/L and
AMH level was 0,04 ng/mL. Despite of the irregular oli-
gomenorrhea, a spontaneous ectopic pregnancy was di-
agnosed in the right fallopian tube in the same year.
After removing the ectopic pregnancy, the irregular oli-
gomenorrhea lasted until 2013, indicating the deterior-
ation of the ovarian follicular pool after cancer
treatment. This was considered as a strong indication
for using the ovarian tissue grafting to obtain the preg-
nancy, when the patient was subsequently counselled for
her wish for motherhood.
The decision to use the heterotopic ovarian transplant-
ation was based on the patient’s clinical conditions, what
prevented the ovarian tissue orthotopic transplantation.
Briefly, recurrent laparoscopies had revealed several pel-
vic pathologies: before and after cancer therapy, recur-
rent cystic benign ovarian tumours were found, arising
from the left ovary. The tumour completely filled the
rectouterine pouch (cavum Douglas) and dislocated the
uterus to the right. In addition, mild endometriosis and
several abdominal adhesions were diagnosed between
the intestines, uterus and tumour tissue. Since the pa-
tient had also a spontaneous ectopic pregnancy in the
right fallopian tube, likely damaging the tissue, the het-
erotopic ovarian tissue transplantation was the only op-
tion to restore her fertility.
Thawing of five ovarian cortical pieces was performed
using the following steps: the cryovials were placed in
the 30 °C water bath until the ice was melted. Then the
pieces of cortical strips were incubated in 1M PrOH
and 0.2M sucrose for 5 min and followed by 0.5M
PrOH and 0.2M sucrose for 5 min in room temperature.
Thereafter the pieces were placed into 0.2M sucrose in
HSA (25 mg/ml) in PBS for 10 min. Heterotopic trans-
plantation was used for thawed pieces of ovarian cortex
into a submuscular pocket on the left side of the lateral
pelvic wall and marked with a metallic marker for better
ultrasound visibility (as shown in Fig. 2).
Ovarian graft stimulation and fertility treatment
After the ovarian tissue transplantation, during the fol-
lowing three months, the FSH level declined to 14,1 U/L
and AMH level raised to 0,3 ng/mL. In the middle of
2013, the patient regained her first spontaneous men-
strual cycle after tissue grafting.
For controlled ovarian hyperstimulation, we classified
the patient as a possible poor ovarian responder, and
used the gonadotropin-releasing hormone (GnRH) agon-
ist long protocol with Diphereline (3.75 mg) administra-
tion started on the 21st cycle day. On the third day after
the beginning of bleeding, the patient started treatment
with exogenous recombinant follicle-stimulating hor-
mone (FSH, Gonal-F, 225 IU per day for 2 days, and 300
IU per day from day 3 to 12). The follicular growth and
endometrial thickness were measured using ultrasound
combined with serum estradiol (E2) measurements to
time the injection of human chorionic gonadotropin
(hCG) for oocyte meiotic resumption. Recombinant
hCG (Ovitrelle, 250 μg) was administered to the patient
and the oocyte pickup (OPU) was performed 36 h later.
On the day of OPU, the patient had three follicles of
≥18mm in the location of the transplanted tissue. Due to
the lack of the follicles, the ovaries remained unpunctured
and the oocytes were only retrieved from the grafted ovar-
ian tissue, excluding any chance for natural conception.
The oocyte retrieval from the transplanted tissue was un-
complicated. All three follicles were aspirated, and two
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oocytes were obtained. After OPU, the patient was treated
with progesterone (Duphaston, 10mg) by oral administra-
tion, until week twelve of gestation. Since the E2 level
dropped in mid-luteal-phase, the E2 (Estrofem, 4mg or-
ally) was also included in the treatment.
Normal IVF was done with both of the oocytes fertil-
ized and one blastocyst was transferred to the uterus on
day 5 after oocyte insemination. A positive serum hCG
test (593.1 IU/l) performed two weeks after embryo
transfer confirmed pregnancy. Subsequently, clinical
pregnancy was ascertained in the sixth week of preg-
nancy, with the gestational sac measured 2.04 cm,
crown-rump length 0.49 cm, and heart beating. The
timely development of the pregnancy per IVF embryo
transfer precluded the natural conception.
At week 28 of pregnancy, gestational diabetes was di-
agnosed, and although the low carbohydrate diet was
recommended for the patient, at week 32, additional
Metformin (500 mg twice per day) was administered.
The healthy boy (3138 g) was born at 39 + 0 weeks of
gestation in April 2014 (Figs. 1 and 3).
The recovery of endogenous ovarian function and follow-
up of the child’s health
By the year of 2016, the computed tomography scans
had not shown any changes in the breast tissue or for-
mation of metastases. The patient had regained regular
28-day menstrual cycles, for the first time after cancer
therapy, indicating the presence of normal ovarian endo-
crine function. Surprisingly, in 2017, the patient had a
spontaneous pregnancy, which could have happened
only via recovery of endogenous ovarian function, be-
cause the conception via heterotopic transplant would
have been possible only using IVF.
At week 20 of the pregnancy, again the gestational dia-
betes was diagnosed and the patient was recommended
low carbohydrate diet. The healthy girl (4100 g) was
born at 39 + 0 of gestation in November 2017.
Both of the children have developed normally without
major complications. However, both of the children have
had some difficulties with the autoimmune diseases such
as atopic dermatitis. Also, the first child was diagnosed
with juvenile arthritis at the age of 3.5 years.
Discussion
Current case study reports the first ovarian tissue cryo-
preservation and heterotopic transplantation for cancer
survivor in Estonia and in Eastern Europe. The following
successful pregnancy resulted in live birth of a healthy
boy in April 2014. Furthermore, years after cancer treat-
ment and ovarian tissue reimplantation, the patient had
a spontaneous pregnancy and a healthy girl was born in
November 2017, indicating the unexpected recovery of
ovarian function.
Ovarian tissue cryopreservation and transplantation
are relatively new and promising options to women with
Fig. 2 Schematic view of the fertility preservation procedures. Based on the patient’s clinical conditions the heterotopic ovarian tissue
transplantation was the only option to restore her fertility after 25 months of cancer diagnosis. (1) 5 pieces of thawed ovarian tissue were
transplanted to the submuscular pocket on the left side of the lateral pelvic wall and marked with a metallic marker for better ultrasound
visibility. (2) The folliculogenesis was stimulated in the transplanted tissue by using exogenous follicle-stimulating hormone. (3) The oocytes were
collected under ultrasound guidance from the grafted tissue (near the metallic marker) only for subsequent (4) IVF and (5) embryo transfer. No
follicles were punctured from the ovaries, thus excluding the chance for the spontaneous pregnancy
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cancer diagnosis to preserve their fertility, as the
chemotherapy-induced follicular depletion may lead to a
loss of menstrual cycle activity that can be transient or
permanent. Our patient received adjuvant chemotherapy
using six cycles of 5-fluorouracil, epirubicin and cyclo-
phosphamide, followed by the radiation therapy. Cyclo-
phosphamide is a highly gonadotoxic alkylating agent
that causes death of primordial and antral follicles lead-
ing to ovarian insufficiency [11, 12]. Indeed, the patient
developed amenorrhea after the initiation of chemother-
apy that evolved to irregular oligomenorrhea after a year.
Despite of achieving an ectopic pregnancy, the persistent
ovulatory dysfunction was considered as a strong indica-
tor for using cryopreserved ovarian tissue grafting to re-
store her fertility. Moreover, due to the other reasons for
impaired fertility (e.g. cystic benign ovarian tumours,
endometriosis and severe pelvic adhesions), the hetero-
topic ovarian tissue transplantation was conducted two
years after the commencement of the cancer therapy.
The folliculogenesis was stimulated in the transplanted
tissue and oocytes were collected for IVF and embryo
transfer. The healthy boy was born after full-term gesta-
tion in 2014, first in Eastern Europe. The possibility of a
natural conception after ovarian tissue grafting cannot
be entirely excluded, and should, therefore, be also ac-
knowledged. Still, after heterotopic tissue transfer, hor-
monal stimulation and IVF embryo transfer, as
implemented in the current case report, the chance for
spontaneous pregnancy did not exist.
Premature ovarian failure after chemotherapy is individ-
ual and dependent upon type and dose of the adminis-
tered cytostatic drug, patients’ age and pretreatment
ovarian reserve [8, 13]. Menstrual cycle resumption may
occur within the first year after chemotherapy [13, 14];
however, there is always uncertainty over the personalised
probability for fertility restoration. A recent study focused
on a very early phase of ovarian function recovery for
young breast cancer patients, claiming that recovery may
follow two different patterns, i.e. demonstrating slow or
fast recovery pattern [13]. In women belonging to the slow
recovery group, all growing follicles are likely destroyed,
possibly due to a higher individual susceptibility to
chemotherapy. Conversely, women with a fast recovery
may still have some antral follicles left, which resume their
growth after the end of treatment [13]. The development
of the primordial follicles from the quiescent state to the
growing antral follicles takes about six months to accom-
plish in human ovaries, explaining the relatively slow cycle
restoration [13, 15]. In certain patients, the restoration, if
any, may take months or even years. Indeed, the patient in
the current study received six cycles of cyclophosphamide
chemotherapy in 2010–2011 and had a slow and partial
recovery to experience irregular oligomenorrhea by the
year 2012.
Fig. 3 First live births after cryopreserved ovarian tissue transplantation to cancer survivors in European countries. By 2014, live births after
cryopreserved ovarian tissue transplantation have been reported in majority of the Western European countries, while Eastern European countries
reported this later than Estonia. Abbreviation: OG ongoing pregnancy. *FertiProtekt cooperation of ca 100 institutions in Germany, Austria
and Switzerland
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However, by the year 2016 the patient had regained
regular 28-day menstrual cycle and had a second child
spontaneously conceived in 2017. This is a strong evi-
dence that endogenous ovary had regained its function
to produce viable follicles and ovulate mature eggs that
are available for fertilization. There may be a possibility
that transplanted ovarian tissue could be beneficial to
the endogenous ovary. Recent study on mice have shown
that grafting from a healthy isogenic ovary to the ovary
of chemo-treated host rescued function and fertility of
the grafted host ovary and resulted in the production of
host-derived offspring [16]. The rescue mechanism is
most probably involved with diffusible paracrine sub-
stance(s) secreted from the donor ovarian tissue. Signals
from transplanted ovarian tissue could prevent apoptosis
of granulosa cells in endogenous ovary, promote the for-
mation of new granulosa cells, or affect the vasculature
or neuronal circuits in the ovary [16]. Moreover, grafted
ovarian tissue may provide a suitable microenvironment
to activate oogonial stem cells in postnatal ovary that
could differentiate to form new follicles [17, 18]. Still,
further elucidation is needed to figure out how grafted
ovarian tissue could influence the function of the cells in
endogenous ovary.
In our case report, two healthy children were born,
one with the aid of heterotopic ovarian tissue transplant-
ation and one through the functional recovery of en-
dogenous ovary. The health and well-being of children
conceived after ovarian tissue transplantation remains
poorly studied [7, 9, 19]. Thus, every successfully con-
ducted ovarian tissue transplantation procedure and the
follow-up information of the child’s health are worth of
reporting. Previous studies have demonstrated that chil-
dren born via ovarian tissue reimplantation have had the
average gestational time of 39 + 0 and normal body
weight [19]. The child in the current case study was
born timely, in 39 + 0 weeks of pregnancy and within
the range of internationally accepted normal body
weight. The overall health of both children has been
good and without major complications. Yet, at the
age of 3–4 years, the boy had been diagnosed with ju-
venile arthritis and both of the children have difficul-
ties with the autoimmune diseases such as atopic
dermatitis. However, there is no evidence whatsoever
for a causal relationship between these diseases and
the mode of conception.
Ovarian tissue cryopreservation and transplantation
have been largely experimental and even forbidden in
several countries, because of the possible risk for reseed-
ing the cancer cells with the tissue grafting. However, re-
cent meta-analyses studies and large case-series of
ovarian tissue transplantations have shown that orthoto-
pic ovarian tissue transplantation is now a valid method
which is expanding beyond the experimental stage and
already has become an established technique for fertility
preservation in multiple centers [19–24]. Yet, there are
only two published case reports that describe successful
pregnancy and live births after heterotopic ovarian tissue
cryopreservation [25, 26], similar to the approach used
in the current report.
In addition, there have been no indications of suffi-
cient numbers of malignant cells present in the ovarian
tissue to cause recurrence of cancer after ovarian tissue
transplantation. Recent analyses have shown that about
7% of patients experience cancer recurrence, but these
have not been associated with grafted ovarian tissue [20,
24, 27]. Jadoul et al. also showed that in favour of ovar-
ian tissue cryopreservation, 96% of patients were found
to be satisfied with the procedure, which brings a sense
of hope to cancer patients to picture themselves in the
future [21].
Over 130 live births are reported globally by multicen-
ter and single case reports [6, 9]. However, global access
to this procedure remains poor. To our knowledge, most
of the successful cases of live births have been reported
in western part of Europe, starting in Belgium in 2004
[8] and soon in Denmark in 2007 [28] (Fig. 3). In 2009,
the first live births were reported in France and Spain
[29, 30]. The cooperation of ca 100 institutions from
Germany, Austria and Switzerland at FertiProtekt an-
nounced their first live birth after cryopreserved ovarian
tissue transplantation in 2011 [31]. Furthermore, there
have been live births also in Italy (2012), Sweden (2013),
Norway (< 2014), United Kingdom (2016) and also one
ongoing pregnancy in Finland [3, 7, 32–35] (Fig. 3). Here
we report the first live birth to a cancer survivor patient
using previously cryopreserved ovarian tissue in Estonia
and also in the eastern part of Europe in 2014 (Fig. 3).
Our case study reveals that many more countries have
started to acknowledge the importance of fertility coun-
selling, giving the opportunity of motherhood to young
female cancer patients.
Conclusion
Despite that many countries have reported the first im-
plementation of the ovarian tissue freezing and trans-
plantation protocols, the data is still limited on the
effectiveness of heterotopic ovarian transplant tech-
niques and more long-term follow-up studies and case
reports are needed to describe ovarian function recovery
and the health of children born. However, the informa-
tion gathered from large national and international mul-
ticentre studies, and clinical case reports from individual
patients is very encouraging that ovarian tissue freezing
and transplantation have completed an important ex-
perimental phase and are ready for wider clinical use in
female fertility preservation.
Tammiste et al. BMC Women's Health           (2019) 19:65 Page 6 of 8
Abbreviations
E2: estradiol; GnRH: gonadotropin-releasing hormone; hCG: human chorionic
gonadotropin; HSA: human serum albumin; IVF: in vitro fertilisation;
OPU: ovum pickup; PrOH: 1,2-propanediol
Acknowledgements
The authors would like to acknowledge the patient for permitting her case
to be reported. The authors would also like to thank the baseline funding of
the University of Tartu.
Funding
The authors were supported during the preparation of the manuscript by
the following funders: the Estonian Ministry of Education and Research
(grant no. IUT34–16), Enterprise Estonia (grant no. EU48695), the Horizon
2020 innovation program (WIDENLIFE, 692065), European Union FP7 Marie
Curie Industry-Academia Partnerships and Pathways funding (IAPP, SARM,
EU324509) and the MSCA-RISE-2015 project MOMENDO (691058).
Availability of data and materials
All data generated or analysed during this study are included in this case report.
Authors’ contributions
TT, PP, KI, KR, PV and AS: management of the patient, acquisition of data,
manuscript writing and revisions. TT, KK, TJ and AS: acquisition of data,
manuscript writing and critical revisions. All the authors read and approved
the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and accompanying images.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1West Tallinn Central Hospital Women’s Clinic, Tallinn, Estonia. 2Internal
Medicine Clinic, Institute of Clinical Medicine, University of Tartu, Tartu,
Estonia. 3Women’s Clinic, Institute of Clinical Medicine, University of Tartu,
Tartu, Estonia. 4Cancer Centre of Tartu University Hospital, Tartu, Estonia.
5Department of Hematology and Oncology, Institute of Clinical Medicine,
University of Tartu, Tartu, Estonia. 6Nova Vita Clinic, Tallinn, Estonia.
7Competence Centre on Health Technologies, Tartu, Estonia. 8Institute of
Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
9Department of Obstetrics and Gynecology, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland.
Received: 9 November 2018 Accepted: 7 May 2019
References
1. Wallace WHB, Anderson RA, Irvine DA. Fertility preservation for young
patients with cancer: who is at risk and what can be offered? Lancet Oncol.
2005;6(4):209–18.
2. Donnez J, Jadoul P, Squifflet J, Van Langendonckt A, Donnez O, Van Eyck A,
et al. Ovarian tissue cryopreservation and transplantation in cancer patients.
Best Practice and Research: Clinical Obstetrics and Gynaecology. 2010;24(1):
87–100.
3. Dunlop CE, Brady BM, McLaughlin M, Telfer EE, White J, Cowie F, et al. Re-
implantation of cryopreserved ovarian cortex resulting in restoration of
ovarian function, natural conception and successful pregnancy after
haematopoietic stem cell transplantation for Wilms tumour. J Assist Reprod
Genet. 2016;33(12):1615–20.
4. Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M,
Schmidt KT, et al. Restoration of ovarian activity and pregnancy after
transplantation of cryopreserved ovarian tissue: a review of 60 cases of
reimplantation. Fertil Steril. 2013;99(6):1503–13.
5. Demeestere I, Simon P, Dedeken L, Moffa F, Tsépélidis S, Brachet C, et al.
Live birth after autograft of ovarian tissue cryopreserved during childhood.
Hum Reprod. 2015;30(9):2107–9.
6. Donnez J, Dolmans MM. The ovary: from conception to death. Fertil Steril.
2017;108(4):594–5.
7. Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, Thurin-Kjellberg A, Nedstrand
E, Kitlinski ML, et al. Ovarian tissue cryopreservation and transplantation
among alternatives for fertility preservation in the Nordic countries –
compilation of 20 years of multicenter experience. Acta Obstet Gynecol
Scand. 2016;95(9):1015–26.
8. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al.
Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.
Lancet. 2004;364(9443):1405–10.
9. Andersen CY, Bollerup AC, Kristensen SG. Defining quality assurance and
quality control measures in connection with ovarian tissue cryopreservation
and transplantation: a call to action. Hum Reprod. 2018;33(7):1201–4.
10. Hreinsson J, Zhang P, Swahn ML, Hultenby K, Hovatta O. Cryopreservation
of follicles in human ovarian cortical tissue. Comparison of serum and
human serum albumin in the cryoprotectant solutions. Hum Reprod. 2003;
18(11):2420–8.
11. Roness H, Kalich-Philosoph L, Meirow D. Prevention of chemotherapy-
induced ovarian damage: possible roles for hormonal and non-hormonal
attenuating agents. Hum Reprod Update. 2014;20(5):759–74.
12. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary:
mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–44.
13. Decanter C, Cloquet M, Dassonneville A, D’Orazio E, Mailliez A, Pigny P.
Different patterns of ovarian recovery after cancer treatment suggest
various individual ovarian susceptibilities to chemotherapy. Reprod BioMed
Online. 2018;36(6):711–8.
14. Jacobson MH, Mertens AC, Spencer JB, Manatunga AK, Howards PP. Menses
resumption after cancer treatment-induced amenorrhea occurs early or not
at all. Fertil Steril. 2016;105(3):765–72.
15. McGee EA, Hsueh AJW. Initial and cyclic recruitment of ovarian follicles.
Endocr Rev. 2000;21(2):200–14.
16. Batchvarov IS, Williamson Taylor R, Bustamante-Marín X, Czerwinski M,
Johnson ES, Kornbluth S, et al. A grafted ovarian fragment rescues host
fertility after chemotherapy. Mol Hum Reprod. 2016;22(12):1–10.
17. Truman AM, Tilly JL, Woods DC. Ovarian regeneration: the potential for
stem cell contribution in the postnatal ovary to sustained endocrine
function. Mol Cell Endocrinol. 2017;445:74–84.
18. Martin J, Woods D, Tilly J. Implications and current limitations of oogenesis
from female germline or Oogonial stem cells in adult mammalian ovaries.
Cells. 2019;8(2):93.
19. Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86
successful births and 9 ongoing pregnancies worldwide in women
transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal
outcome in 40 of these children. J Assist Reprod Genet. 2017;34(3):325–36.
20. Gellert SE, Pors SE, Kristensen SG, Bay-Bjørn AM, Ernst E, Yding Andersen C.
Transplantation of frozen-thawed ovarian tissue: an update on worldwide
activity published in peer-reviewed papers and on the Danish cohort. J
Assist Reprod Genet. 2018;35(4):561–70.
21. Jadoul P, Guilmain A, Squifflet J, Luyckx M, Votino R, Wyns C, et al. Efficacy
of ovarian tissue cryopreservation for fertility preservation: lessons learned
from 545 cases. Hum Reprod. 2017;32(5):1046–54.
22. Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med.
2017;377(17):1657–65.
23. Van der Ven H, Liebenthron J, Beckmann M, Toth B, Korell M, Krüssel J, et al.
Ninety-five orthotopic transplantations in 74 women of ovarian tissue after
cytotoxic treatment in a fertility preservation network: tissue activity,
pregnancy and delivery rates. Hum Reprod. 2016;31(9):2031–41.
24. Pacheco F, Oktay K. Current success and efficiency of autologous ovarian
transplantation: a meta-analysis. Reprod Sci. 2017;24(8):1111–20.
25. Stern CJ, Gook D, Hale LG, Agresta F, Oldham J, Rozen G, et al. First reported
clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue
in a woman after a bilateral oophorectomy. Hum Reprod. 2013;28(11):2996–9.
26. Stern CJ, Toledo MG, Hale LG, Gook DA, Edgar DH. The first Australian
experience of heterotopic grafting of cryopreserved ovarian tissue: evidence
of establishment of normal ovarian function. Aust New Zeal J Obstet
Gynaecol. 2011;51(3):268–75.
Tammiste et al. BMC Women's Health           (2019) 19:65 Page 7 of 8
27. Jensen AK, Kristensen SG, MacKlon KT, Jeppesen JV, Fedder J, Ernst E, et al.
Outcomes of transplantations of cryopreserved ovarian tissue to 41 women
in Denmark. Hum Reprod. 2015;30(12):2838–45.
28. Andersen CY, Rosendahl M, Byskov AG, Loft A, Ottosen C, Dueholm M, et al.
Two successful pregnancies following autotransplantation of frozen/thawed
ovarian tissue. Hum Reprod. 2008;23(10):2266–72.
29. Roux C, Amiot C, Agnani G, Aubard Y, Rohrlich P-S, Piver P. Live birth after
ovarian tissue autograft in a patient with sickle cell disease treated by
allogeneic bone marrow transplantation. Fertil Steril. 2010;93(7):2413.e15–9.
30. Sánchez-Serrano M, Crespo J, Mirabet V, Cobo AC, Escribá MJ, Simón C, et
al. Twins born after transplantation of ovarian cortical tissue and oocyte
vitrification. Fertil Steril. 2010;93(1):268.e11–3.
31. Müller A, Keller K, Wacker J, Dittrich R, Keck G, Montag M, et al.
Retransplantation of cryopreserved ovarian tissue: the first live birth in
Germany. Dtsch Ärzteblatt Int. 2012;109(1–2):8–13.
32. Revelli A, Marchino G, Dolfin E, Molinari E, Delle Piane L, Salvagno F, et al.
Live birth after orthotopic grafting of autologous cryopreserved ovarian
tissue and spontaneous conception in Italy. Fertil Steril. 2013;99(1):227–30.
33. Rodriguez-Wallberg KA, Karlström PO, Rezapour M, Castellanos E, Hreinsson
J, Rasmussen C, et al. Full-term newborn after repeated ovarian tissue
transplants in a patient treated for Ewing sarcoma by sterilizing pelvic
irradiation and chemotherapy. Acta Obstet Gynecol Scand. 2015;94(3):324–8.
34. Tanbo T, Greggains G, Storeng R, Busund B, Langebrekke A, Fedorcsak P.
Autotransplantation of cryopreserved ovarian tissue after treatment for
malignant disease - the first Norwegian results. Acta Obstet Gynecol Scand.
2015;94(9):937–41.
35. The ESHRE Working Group on Oocyte Cryopreservation in Europe, Shenfield
F, de Mouzon J, Scaravelli G, Kupka M, Ferraretti AP, Prados FJ, et al. Oocyte
and ovarian tissue cryopreservation in European countries: statutory
background, practice, storage and use. Hum Reprod Open. 2017. https://doi.
org/10.1093/hropen/hox003.
Tammiste et al. BMC Women's Health           (2019) 19:65 Page 8 of 8
